Immuno-PET
PET scans built from radiolabelled antibodies or their fragments, to see any protein an antibody can reach, including immune cells inside tumours.
Overview
Immuno-PET attaches long-lived positron emitters such as 89Zr or 64Cu to antibodies, minibodies or nanobodies, so that any protein an antibody can reach can be imaged across the whole body. It covers 89Zr-antibody imaging of ADC targets including TROP2 and HER2, and T-cell imaging with 89Zr-crefmirlimab berdoxam, a CD8 minibody, and 18F-AraG, which marks activated T cells. CD8 PET is in phase 2/3 as a pharmacodynamic and predictive biomarker for checkpoint inhibitors, aiming to show whether T cells are entering tumours early in treatment. The strengths are non-invasive imaging of target and immune infiltrate, and the fact that any antibody can be turned into a tracer. Full antibodies have slow kinetics, requiring days before imaging, and 89Zr is costly. Immuno-PET turns therapeutic antibodies into imaging agents that show where their targets and the immune cells are.
- Detector ring
- CD8 minibody (T cells)
- 511 keV photon pair
How it works
Long-lived positron emitters (89Zr, 64Cu) chelated to antibodies, minibodies, or nanobodies.
- Images target and immune infiltrate non-invasively
- Any antibody can be turned into a tracer
- Slow kinetics for full antibodies
- Cost of 89Zr
Dependencies
Open the dependency map →Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.
Latest papers
topQuery for this technology: (TITLE:"immuno-PET" OR ABSTRACT:"immuno-PET" OR TITLE:"immunoPET" OR ABSTRACT:"immunoPET" OR TITLE:"CD8 PET" OR ABSTRACT:"CD8 PET" OR TITLE:"89Zr-labeled antibody" OR ABSTRACT:"89Zr-labeled antibody"). Results are unfiltered search hits about Immuno-PET, not a curated reading list.
Similar pages
not linked directly; found by shared links- IndicationTriple-negative breast cancer
Shares Sortilin (SORT1), TROP2 imaging where no tissue test is required, TROP2, TROP2 PET.
- TargetHER3 (ERBB3)
Shares HER3 imaging, and why three tracers stalled, HER2, Zirconium-89, Copper-64.
- PersonShaoli Song
- TrialZIRCON
Shares Zirconium-89 girentuximab, CAIX PET (89Zr-girentuximab), Zirconium-89.
- IdeaAlpha radioligands after ADC failure
- TargetCAIX (carbonic anhydrase IX)
Shares Zirconium-89 girentuximab, CAIX imaging of the indeterminate renal mass, CAIX PET (89Zr-girentuximab).
- IndicationRenal cell carcinoma
Shares ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma, Zirconium-89 girentuximab, CAIX imaging of the indeterminate renal mass, CAIX PET (89Zr-girentuximab).
- TechnologyFES PET (oestrogen receptor imaging)
Shares HER2 PET, PET (positron emission tomography), PET/CT, Fluorine-18.